scholarly journals TaqMan Real-Time Quantification of Epstein-Barr Virus in Severe Early Childhood Caries

2010 ◽  
Vol 04 (01) ◽  
pp. 028-033 ◽  
Author(s):  
Sibel Yildirim ◽  
Esma Yildiz ◽  
Ayhan Kubar
Keyword(s):  
Early Childhood ◽  
Real Time ◽  
Early Childhood Caries ◽  
Epstein Barr Virus ◽  
Post Treatment ◽  
Barr Virus ◽  
Supragingival Plaque ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Childhood Caries

ABSTRACTObjectives: Early childhood caries (ECC) has several risk factors and it is important stressful/ painful events of childhood and immunosuppression may occur during this unique rampant caries pattern. The changes in the host immune competence by compromised cellular immune system functions can activate Epstein Barr virus (EBV). The objective of this study was to determine whether the supragingival plaque samples of severe-ECC (S-ECC) patients harbor more EBV load than the non-carious healthy children by quantitative TaqMan Real-Time polymerase chain reaction (PCR).Methods: Sixty subjects, including 30 S-ECC patients as well as age and gender matched 30 caries- free patients were studied. The supragingival plaque samples were collected from patients by brushing their teeth for 1 minute and the toothbrush was washed in 1 ml of sterile deionized water. After viral DNA extraction, TaqMan real-time PCR assay was used to quantify EBV DNA. Dental treatments were completed for all S-ECC patients and they were called for routine controls. Only 10 treated S-ECC patients were come to the 3rd months’ control and post-treatment viral sampling was made in the same manner.Results: EBV DNA was detected 16 of 30 S-ECC patients and 6 of the healthy controls (P<.001). There was no relationship between baseline and post-treatment samples of 10 treated S-ECC patients.Conclusions: The results of the study suggest that oro-dental hygiene motives of S-ECC patients might be important contributory factor for S-ECC and EBV would not be involved in the etiopathogenesis of ECC. (Eur J Dent 2010;4:28-33)

Longitudinal circulating Epstein–Barr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6021-6021
Author(s):  
Jia-Wei Lv ◽  
Ying Sun ◽  
Yu-Pei Chen ◽  
Guan-Qun Zhou ◽  
Kuan Rui Lloyd Tan ◽  
...  
Keyword(s):  
Real Time ◽  
Induction Chemotherapy ◽  
Epstein Barr Virus ◽  
Locally Advanced ◽  
Treatment Resistant ◽  
Barr Virus ◽  
Longitudinal Response ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Pre Treatment

6021 Background: Liquid biopsies have the utility for detecting minimal residual disease in several cancers, but its clinical utility for real-time treatment adaptation remains limited. We adopted Epstein-barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) as a model to investigate its potential. We characterize longitudinal response of circulating EBV DNA to induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT) in locally advanced NPC (LA-NPC), and investigate the association of complete biological response (cBR, undetectable cfEBV DNA) during treatment to prognoses. Methods: The medical records of 673 LA-NPC cases with serial EBV DNA measurements (pre-treatment, after each IC cycle, post-CCRT) were extracted. Cox regression and landmark analysis were used for survival analyses. Results: Four distinct phenotypes were identified based on their longitudinal cfEBV DNA response: 1) Early responders (200/673[29.7%]) achieved cBR post-IC1; 2) Intermediate responders (332/673[49.3%]) included patients with cBR post-IC2-4, and cBR post-CCRT after two IC cycles or following a temporary bounce (detectable reading following initial cBR); 3) Late responders (75/673[11.2%]) achieved cBR only post-CCRT after 3-4 IC cycles; 4) Treatment-resistant (66/673[9.8%]) patients demonstrated non-cBR post-IC+CCRT. These phenotypes were significantly correlated with prognoses, adjusted for pre-treatment EBV DNA load, N-category and chemotherapy intensity (AHRDFS = 3.46[2.01–6.25], intermediate; 7.50[4.24–14.77], late; 17.33[10.06–33.38], treatment-resistant vs. early responders, Pall < 0.01). Interestingly, intermediate and late responders without cBR post-IC2 had inferior survival despite more IC (HRDFS = 1.83[1.17–2.84], > 2 vs. >2 IC cycles, P < 0.01). For treatment-resistant patients, adjuvant chemotherapy following IC+CCRT reduced risk of distant metastasis (HRDMFS = 0.42[0.24–0.74], P < 0.01). Conclusions: We propose investigate risk-adapted chemotherapy de-intensification and intensification strategies based on the four novel phenotypes, which could shape the individualized treatment of LA-NPC. Our study highlights the feasibility of liquid biopsy for real-time therapeutic adaptation.

Quantitative Analysis of Epstein-Barr Virus Load by Using a Real-Time PCR Assay

1999 ◽  
Vol 37 (1) ◽  
pp. 132-136 ◽  
Author(s):  
Hiroshi Kimura ◽  
Makoto Morita ◽  
Yumi Yabuta ◽  
Kiyotaka Kuzushima ◽  
Koji Kato ◽  
...  
Keyword(s):  
Real Time ◽  
Infectious Mononucleosis ◽  
Real Time Pcr ◽  
Copy Number ◽  
Epstein Barr Virus ◽  
Pcr Assay ◽  
Virus Load ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

To measure the virus load in patients with symptomatic Epstein-Barr virus (EBV) infections, we used a real-time PCR assay to quantify the amount of EBV DNA in blood. The real-time PCR assay could detect from 2 to over 107 copies of EBV DNA with a wide linear range. We estimated the virus load in peripheral blood mononuclear cells (PBMNC) from patients with symptomatic EBV infections. The mean EBV-DNA copy number in the PBMNC was 103.7 copies/μg of DNA in patients with EBV-related lymphoproliferative disorders, 104.1 copies/μg of DNA in patients with chronic active EBV infections, and 102.2copies/μg of DNA in patients with infectious mononucleosis. These numbers were significantly larger than those in either posttransplant patients or immunocompetent control patients without EBV-related diseases. In a patient with infectious mononucleosis, the virus load decreased as the symptoms resolved. The copy number of EBV DNA in PBMNC from symptomatic EBV infections was correlated with the EBV-positive cell number determined by the in situ hybridization assay (r = 0.842; P < 0.0001). These results indicate that the real-time PCR assay is useful for diagnosing symptomatic EBV infection and for monitoring the virus load.

scholarly journals Association of subgingival Epstein–Barr virus and periodontitis

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 414
Author(s):  
Chaerita Maulani ◽  
Sri Lelyati C. Masulili ◽  
Widayat Djoko Santoso ◽  
Nurtami Soedarsono ◽  
Lindawati Kusdhany ◽  
...  
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Gingival Crevicular Fluid ◽  
Barr Virus ◽  
Severe Periodontitis ◽  
Significant Difference ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Crevicular Fluid

Background: The Epstein–Barr virus (EBV) is gaining interest as a possible agent in the etiology of periodontitis. Previous studies have shown controversy on whether EBV DNA in the subgingival periodontal pockets is associated with periodontitis. The present study aimed to seek the potential relationship between EBV and periodontitis. Methods: Samples were taken from gingival crevicular fluid using sterile paper points, and data on sociodemographics, oral health, and periodontal health were recorded. This case-control study of 118 participants included 59 subjects with severe periodontitis and 59 control subjects with mild periodontitis. Quantitative real-time PCR was used to determined EBV load. Results: EBV DNA was detected in 37.3% of the case samples and 18.6% of the control samples. There was no significant difference in a load of EBV DNA between severe and mild periodontitis (p>0.05). The observed load of EBV DNA was up to 4.55x10 5 copies/mL. The detected EBV DNA was significantly associated with the plaque index and the oral hygiene index (p<0.05). Conclusions: Although no significant association was found, EBV may play a role in periodontitis. The real-time PCR methods can be used to monitor the EBV load in gingival crevicular fluid.

scholarly journals Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Lisheng Zhu ◽  
Tao Ouyang ◽  
Ying Xiong ◽  
Li Ba ◽  
Qiuting Li ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Prognostic Value ◽  
Epstein Barr Virus ◽  
Progression Free Survival ◽  
Post Treatment ◽  
Rank Test ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

BackgroundIn this study, we evaluated the prognostic value of the plasma levels of Epstein-Barr virus (EBV) DNA in patients with nasopharyngeal carcinoma (NPC) at different treatment stages.MethodsWe retrospectively analyzed the Data of 206 patients with NPC. Pre-neoadjuvant chemotherapy (pre-NACT), post-NACT, post-radiotherapy, and post-treatment plasma EBV DNA levels were used to establish prognostic nomograms. The concordance index (C-index) and calibration curves were used to compare the prognostic accuracy of the nomograms. The results were confirmed in a validation cohort consisting of patients who were tested for EBV DNA levels at all four stages of treatment. The Kaplan-Meier method was used to calculate the progression-free survival (PFS) and overall survival (OS). Survival differences were calculated using the log-rank test.ResultsEBV DNA-positive patients had worse 3-year PFS and 5-year OS than EBV DNA-negative patients; this was true for pre-NACT (PFS: 82.7% vs. 57.3%, P &lt; 0.001; OS: 90.9% vs. 68.7%, P = 0.08) and post-NACT (PFS: 85.0% vs. 50.6%, P &lt; 0.001; OS: 91.7% vs. 65.7%; P = 0.001) EBV DNA levels but not for post-radiotherapy (PFS: 72.2% vs. 60.9%, P = 0.192; OS: 73.1% vs. 77.2%, P = 0.472) or post-treatment (PFS: 77.3% vs. 59.2%, P = 0.063; OS: 77.5% vs. 79.7%, P = 0.644) levels. Nomograms combining pre-NACT and post-NACT EBV DNA levels had a superior prognostic ability than those of post-radiotherapy and post-treatment EBV DNA levels.ConclusionPre-NACT EBV DNA levels combined with post-NACT EBV DNA levels can more reliably predict survival outcomes in patients with NPC.

scholarly journals Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus

2000 ◽  
Vol 38 (2) ◽  
pp. 712-715 ◽  
Author(s):  
Hubert G. M. Niesters ◽  
Joost van Esser ◽  
Edwin Fries ◽  
Katja C. Wolthers ◽  
Jan Cornelissen ◽  
...  
Keyword(s):  
Real Time ◽  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ ◽  
Plasma Samples ◽  
Serum Samples ◽  
Barr Virus ◽  
Transplant Patients ◽  
Ebv Dna ◽  
Epstein Barr

With the use of real-time PCR, we developed and evaluated a rapid, sensitive, specific, and reproducible method for the detection of Epstein-Barr virus (EBV) DNA in plasma samples. This method allowed us to screen plasma and serum samples over a range between 100 and 107 copies of DNA per ml using two sample preparation methods based on absorption. A precision study yielded an average coefficient of variation for both methods of less than 12%, with a coefficient of regression for the standard curve of a minimum of 0.98. We detected EBV DNA in 19.2% of plasma samples from immunosuppressed solid-organ transplant patients without symptoms of EBV infections with a mean load of 440 copies per ml. EBV DNA could be detected in all transplant patients diagnosed with posttransplant lymphoproliferative disorder, with a mean load of 544,570 copies per ml. No EBV DNA could be detected in healthy individuals in nonimmunosuppressed control groups and a mean of 6,400 copies per ml could be detected in patients with infectious mononucleosis. Further studies revealed that the inhibitory effect of heparinized plasma could be efficiently removed by use of an extraction method with Celite as the absorbent.

scholarly journals Comparison of commercial and in-house Real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in plasma

2007 ◽  
Vol 7 (1) ◽  
pp. 22 ◽  
Author(s):  
Francesca Perandin ◽  
Elisabetta Cariani ◽  
Caterina Pollara ◽  
Nino Manca
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Ebv Dna ◽  
Pcr Assays ◽  
Epstein Barr

scholarly journals Association of subgingival Epstein–Barr virus and periodontitis

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 414
Author(s):  
Chaerita Maulani ◽  
Sri Lelyati C. Masulili ◽  
Widayat Djoko Santoso ◽  
Nurtami Soedarsono ◽  
Lindawati Kusdhany ◽  
...  
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Gingival Crevicular Fluid ◽  
Barr Virus ◽  
Severe Periodontitis ◽  
Significant Difference ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Crevicular Fluid

Background: The Epstein–Barr virus (EBV) is gaining interest as a possible agent in the etiology of periodontitis. Previous studies have shown controversy on whether EBV DNA in the subgingival periodontal pockets is associated with periodontitis. The aim of the present study was to seek the potential relationship between EBV and periodontitis. Methods: Data on socio-demographics, oral health, and periodontal health were recorded, and samples were collected from gingival crevicular fluid, using sterile paper point. This case–control study of 118 participants included 59 subjects with severe periodontitis and 59 control subjects with mild periodontitis. The EBV load was determined by quantitative real-time PCR. Results: EBV DNA was detected in 37.3% of the case samples and in 18.6% of the control samples. There was no significant difference in the load of EBV DNA between severe and mild periodontitis (p>0.05). The observed load of EBV DNA was up to 4.55x105 copies/mL. The detected EBV DNA was significantly associated with the plaque index and the oral hygiene index (all p<0.05). Conclusions: A significant association was not found, but EBV might contribute to periodontitis. Gingival crevicular fluid is useful for monitoring the EBV load by the real-time PCR technique.

Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies

2000 ◽  
Vol 111 (1) ◽  
pp. 239-246 ◽  
Author(s):  
Kenny I. K. Lei ◽  
Lisa Y.S. Chan ◽  
Wing Y. Chan ◽  
Philip J. Johnson ◽  
Y. M. Dennis Lo
Keyword(s):  
Quantitative Analysis ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Lymphoid Malignancies ◽  
Ebv Dna ◽  
Epstein Barr

Association of normal oral mucosa with DNA of the main types of oncogenic viruses

2020 ◽  
pp. 60-63
Author(s):  
S.I. Kutukova ◽  
A.B. Chukhlovin ◽  
A.I. Yaremenko ◽  
Yu.V. Ivaskova ◽  
A.Ya. Razumova ◽  
...  
Keyword(s):  
Oral Mucosa ◽  
Epstein Barr Virus ◽  
Oncogenic Viruses ◽  
Viral Dna ◽  
Dna Viruses ◽  
Normal Oral Mucosa ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Hpv 18

The aim of the study was to assess the prevalence of DNA viruses (HSV I and II, CMV, EBV, HPV6.11, HPV16 and HPV18) in the native oral mucosa of healthy volunteers (n=50; 30 men (60.0%), 20 women (40.0%); 25—74 years, median age — 55.0 years (95% CI 47.60-56.76)). All samples of the normal oral mucosa were detected by real-time PCR to detect viral DNA. The majority of the examined — 76% (33/50) — revealed the DNA: one type of viral DNA in 17 (38.00%) of the examined, a combination of the two types in 14 (28.00%). In the normal oral mucosa, DNA of Epstein-Barr virus was significantly more often detected: 15 (30.00%) (p = 0.0276) and human papilloma viruses 27 (54.00%) (p <0.0001), especially HPV-18 (24 (48.00%)): mono-association in 9 (18.00%) examined and in 7 (14.00%) in combination with EBV DNA (p = 0.0253).

scholarly journals Circulating cell‐free epstein–barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Amina Gihbid ◽  
Raja Benzeid ◽  
Abdellah Faouzi ◽  
Jalal Nourlil ◽  
Nezha Tawfiq ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Lymph Node ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Disease Stage ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Pre Treatment ◽  
Moroccan Patients

Abstract Background The identification of effective prognosis biomarkers for nasopharyngeal carcinoma (NPC) is crucial to improve treatment and patient outcomes. In the present study, we have attempted to evaluate the correlation between pre-treatment plasmatic Epstein-Barr virus (EBV) DNA load and the conventional prognostic factors in Moroccan patients with NPC. Methods The present study was conducted on 121 histologically confirmed NPC patients, recruited from January 2017 to December 2018. Circulating levels of EBV DNA were measured before therapy initiation using real-time quantitative PCR. Results Overall, undifferentiated non-keratinizingcarcinoma type was the most common histological type (90.1 %), and 61.8 % of patients were diagnosed at an advanced disease stage (IV). Results of pre-treatment plasma EBV load showed that 90.9 % of patients had detectable EBV DNA, with a median plasmatic viral load of 7710 IU/ml. The correlation between pre-treatment EBV DNA load and the conventional prognostic factors showed a significant association with patients’ age (p = 0.01), tumor classification (p = 0.01), lymph node status (p = 0.003), metastasis status (p = 0.00) and overall cancer stage (p = 0.01). Unexpectedly, a significant higher level of pre-treatment EBV DNA was also found in plasma of NPC patients with a family history of cancer (p = 0.04). The risk of NPC mortality in patients with high pretreatment EBVDNA levels was significantly higher than that of those with low pre-treatment plasma EBV-DNA levels (p < 0.05). Furthermore, patients with high pre-treatment EBV-DNA levels (≥ 2000, ≥ 4000) had a significant low overall survival (OS) rates (p < 0.05). Interestingly, lymph node involvement, metastasis status and OS were found to be the most important factors influencing the EBV DNA load in NPC patients. Conclusions The results of the present study clearly showed a high association between pre-treatment EBV DNA load, the crucial classical prognostic factors (T, N, M and disease stage) of NPC and OS, suggesting that pre-treatment EBV DNA can be a useful prognostic biomarker in clinical decision-making and improving NPC treatment in Morocco.

Sign in / Sign up

Export Citation Format

Share Document